Andrew Bowden - Item 9 Pres CEO
| INLB Stock | USD 0.0001 0.00 0.00% |
Insider
Andrew Bowden is Pres CEO of Item 9 Labs
| Age | 34 |
| Phone | 833 867 6337 |
| Web | https://www.item9labscorp.com |
Item 9 Management Efficiency
The company has return on total asset (ROA) of (0.0721) % which means that it has lost $0.0721 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4212) %, meaning that it created substantial loss on money invested by shareholders. Item 9's management efficiency ratios could be used to measure how well Item 9 manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Shay Levav | Icecure Medical | 47 | |
| William MBA | STRATA Skin Sciences | 58 | |
| John Wilson | Rapid Micro Biosystems | 56 | |
| Shunichi Kuroda | Bone Biologics Corp | N/A | |
| Eyal Shamir | Icecure Medical | 63 | |
| Jennifer Ernst | Tivic Health Systems | 56 | |
| Avner Hagai | Brainsway | 68 | |
| Blake Gurfein | Tivic Health Systems | 40 | |
| Christopher Lesovitz | STRATA Skin Sciences | 41 | |
| Soren Sinay | Venus Concept | 53 | |
| Pr Zangen | Brainsway | 54 | |
| Robert Moccia | STRATA Skin Sciences | 65 | |
| Naum Muchnik | Icecure Medical | 48 | |
| Richard Areglado | Brainsway | 60 | |
| Eric Pauls | Tactile Systems Technology | 49 | |
| Darrell Rigel | STRATA Skin Sciences | 73 | |
| Ronen CPA | Icecure Medical | 55 | |
| Yiftach Roth | Brainsway | 53 | |
| Michael Goodman | STRATA Skin Sciences | N/A | |
| Richard Ginn | Tenon Medical | 58 | |
| Janelle Strop | Tactile Systems Technology | N/A | |
Management Performance
| Return On Equity | -0.42 | |||
| Return On Asset | -0.0721 |
Item 9 Labs Leadership Team
Elected by the shareholders, the Item 9's board of directors comprises two types of representatives: Item 9 inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Item. The board's role is to monitor Item 9's management team and ensure that shareholders' interests are well served. Item 9's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Item 9's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mike II, G Counsel | ||
| Christopher Wolven, Chief Officer | ||
| Jayne Levy, VP Communications | ||
| Kyle Jennings, Vice President | ||
| Robert Mikkelsen, Treasurer Sec | ||
| Michael Weinberger, Chief Director | ||
| Cory Carter, VP Cultivation | ||
| Mark Busch, Sr Devel | ||
| Andrew Bowden, Pres CEO |
Item Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Item 9 a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.42 | |||
| Return On Asset | -0.0721 | |||
| Profit Margin | (1.43) % | |||
| Operating Margin | (0.60) % | |||
| Current Valuation | 52.06 M | |||
| Shares Outstanding | 100 M | |||
| Shares Owned By Insiders | 25.71 % | |||
| Price To Book | 0.28 X | |||
| Price To Sales | 0.95 X | |||
| Revenue | 21.76 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Item Pink Sheet
Item 9 financial ratios help investors to determine whether Item Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Item with respect to the benefits of owning Item 9 security.